Literature DB >> 1655987

The treatment of Wilms' tumor patients with pulmonary metastases detected only with computed tomography: a report from the National Wilms' Tumor Study.

D M Green1, D J Fernbach, P Norkool, G Kollia, G J D'Angio.   

Abstract

To evaluate the prognosis of patients with Wilms' tumor who have pulmonary densities identified on a computed tomographic (CT) scan of the chest, but have a negative plain chest radiograph, we reviewed the treatments and outcome of 32 patients randomized or followed on National Wilms' Tumor Study (NWTS)-3. The 4-year event-free and overall survival percentages of 18 of these patients who had a favorable histology tumor and were treated as stage IV tumors with three or four drugs plus whole-lung irradiation were 88.1% and 94.0%, respectively. The 4-year event-free and overall survival percentages for nine favorable histology patients treated less aggressively based on the extent of locoregional disease with two or three drugs and without whole-lung irradiation were 88.9% and 88.0%, respectively. There were no statistically significant differences in the 4-year event-free or overall survival percentages between the two groups. The current data do not demonstrate improved survival for favorable histology patients treated with whole-lung irradiation for pulmonary metastases identified only on chest CT scan. However, due to the small number of patients included, no statistically valid conclusions regarding the roles of Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) and/or whole-lung irradiation in the treatment of these patients can be drawn from the present analysis. Additional patients need to be systematically studied to determine if these preliminary observations can be confirmed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655987     DOI: 10.1200/JCO.1991.9.10.1776

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

Review 1.  Wilms tumor: what's new?

Authors:  Tomás Acha García; Carlota Calvo Escribano; José Alfaro Gutiérrez; Paloma Galarón García; Mercedes Guibelalde del Castillo
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

2.  FDG positron emission tomography/computed tomography studies of Wilms' tumor.

Authors:  A K M Moinul Hossain; Barry L Shulkin; Michael J Gelfand; Humayun Bashir; Najat C Daw; Susan E Sharp; Helen R Nadel; Jeffrey S Dome
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

3.  Commentary: imaging and staging of Wilms' tumors: problems and controversies.

Authors:  M D Cohen
Journal:  Pediatr Radiol       Date:  1996

4.  Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: a report from the Children's Oncology Group.

Authors:  Paul E Grundy; Daniel M Green; Astrid C Dirks; Andrea E Berendt; Norman E Breslow; James R Anderson; Jeffrey S Dome
Journal:  Pediatr Blood Cancer       Date:  2012-03-15       Impact factor: 3.167

Review 5.  Imaging in unilateral Wilms tumour.

Authors:  Hervé J Brisse; Anne M Smets; Sue C Kaste; Catherine M Owens
Journal:  Pediatr Radiol       Date:  2007-11-16

Review 6.  Imaging in childhood cancer: a Society for Pediatric Radiology and Children's Oncology Group Joint Task Force report.

Authors:  Daniel A Weiser; Sue C Kaste; Marilyn J Siegel; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2013-04-09       Impact factor: 3.167

Review 7.  Wilms tumour: diagnosis and treatment.

Authors:  M J Coppes; J E Wolff; M L Ritchey
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.930

Review 8.  Multidisciplinary Treatment Strategies for Wilms Tumor: Recent Advances, Technical Innovations and Future Directions.

Authors:  Till-Martin Theilen; Yannick Braun; Konrad Bochennek; Udo Rolle; Henning C Fiegel; Florian Friedmacher
Journal:  Front Pediatr       Date:  2022-07-14       Impact factor: 3.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.